Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Haff disease is a rare syndrome characterized by rhabdomyolysis within 24 hours of fish consumption. Despite the recognition of acute kidney injury (AKI) as a major complication, the heterogeneity of clinical presentation and the epidemiological rarity of the condition pose significant challenges to effective prognostic assessment. This study aims to investigate the main differences in clinical presentation and laboratory findings between patients with and without AKI in Haff disease.
This is a retrospective cohort study using medical records from a tertiary hospital between 2021 and 2022 in Brazil. We included adult patients who presented with serum creatine phosphokinase (CPK) levels at least five times the upper limit of normal, associated with classic signs of rhabdomyolysis—such as myalgia, weakness, and dark urine—within 24 hours of fish consumption.
A total of 18 cases were included, most of whom were male (56%), with a mean age of 52.6 ± 16.4 years; 28% had diabetes, and 39% had hypertension. AKI occurred in 8 patients (44%), with the majority classified as KDIGO stage 3 (75% of cases). In the AKI group, 2 (25%) patients presented with oliguria, 5 (63%) required dialysis, and 3 (38%) were discharged still requiring dialysis. The two patients who required intensive care belonged to the AKI group. CPK levels did not differ between the groups but were substantially elevated across the entire cohort (19700 [5800 – 22000] U/L). Peak levels of liver enzymes (AST: 1090 [376 – 1606] vs. 221 [156 – 258] U/L, p=0.005; and ALT: 539 [226 – 900] vs. 140 [91 – 198] U/L, p=0.018) and Lactate Dehydrogenase (5365 [2894 – 6807] vs. 1276 [481 – 1616] U/L, p=0.042) were significantly higher in the AKI group. Both admission CK-MB (1474 [841 – 2570] vs. 307 [208 – 629] U/L, p=0.008) and peak CK-MB levels (1839 [1110 – 2570] vs. 316 [267 – 629] U/L, p=0.003) were also significantly elevated in patients with AKI.
The incidence of AKI in our cohort exceeded previously reported rates in Haff disease, and patients with AKI had worse clinical trajectories, accounting for all ICU admissions. Despite medical intervention, some remained dialysis-dependent at discharge, suggesting potentially irreversible kidney damage.
